Current Clinical Trials

The Emphysema and COPD Research Center is participating in several clinical research studies investigating newer treatments for patients with COPD.
In addition, it maintains an active registry for patient participation in clinical research trials. The current research activities include:

Evaluate Targeted Lung Denervation (bronchoscopic ablation of pulmonary vagus nerve) to reduce COPD exacerbations in GOLD E (Exacerbation at risk) COPD patients (Nuvaira Airflow-3)

To demonstrate the superiority of treatment with the Nuvaira Lung Denervation System compared to a sham procedure to decrease moderate or severe exacerbations in subjects with COPD already treated with appropriate inhale. This involves bronchoscopic ablation of pulmonary vagus nerve surrounding the main bronchi.

ClinicalTrials.gov Identifier: NCT03639051

Evaluate Benralizumab (mAb against IL-5 receptor alpha) to reduce COPD exacerbations in Gold E COPD patients with eosinophilia (RESOLUTE)

To evaluate the efficacy and safety of a Benralizumab (monoclonal antibody directed against IL-5 receptor alpha) in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).

ClinicalTrials.gov Identifier: NCT04053634

Evaluate Tozorakimab (mAB against IL-33) to reduce COPD exacerbations and improve FEV1 in Gold E COPD patients (OBERON)

To evaluate the efficacy and safety of tozorakimab (monoclonal antibody that binds IL-33) in patients with COPD and history of ≥ 1 exacerbation and/or symptoms of chronic bronchitis. IL-33 is a proinflammatory cytokine causing inflammation, goblet cell hypertrophy and mucus hypersecretion.

ClinicalTrials.gov Identifier: NCT05166889, NCT04631016

Compare Roflumilast vs Azithromycin to prevent COPD exacerbation in COPD patient hospitalized with acute exacerbation in the last 1 year (RELIANCE)

To compare the effectiveness of two available medications, roflumilast 500 mcg daily versus azithromycin (250 mg QD or 500 mg QD three times per week), to prevent hospitalization or death in patients with COPD who were hospitalized due to COPD exacerbation in last 1 year.

ClinicalTrials.gov Identifier: NCT04069312

Evaluate High Flow Nasal therapy via myAirvo 3 to increase time to first exacerbation and decrease mortality in COPD patient hospitalized with acute exacerbation in last 6 weeks (HiFloCOPD)

To determine if humidified high flow nasal therapy delivered via myAirvo 3 in addition to the usual COPD medical care increases the time to first moderate-severe exacerbation or all-cause mortality in patients with moderate to very severe COPD with recent exacerbation requiring hospitalization.

ClinicalTrials.gov Identifier: NCT05204888

American Lung Association: Lung Health Cohort: To Establish a cohort of healthy 25–35 years olds to understand the onset of lung disease.

A longitudinal cohort study enrolling young adults between the ages of 25-35 who do not have severe lung disease. The objective is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

ClinicalTrials.gov Identifier: NCT04543461

Current Clinical Trials

Please Click the Study Name For More Detailed Information On Any of the Studies Above

Thank You

For Contacting Us!